Transcriptional regulation of effector and memory CD8+ T cell fates.

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50

Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med (2015) 1.58

CD4+ T cell effector commitment coupled to self-renewal by asymmetric cell divisions. J Exp Med (2016) 0.81

Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Semin Immunol (2015) 0.77

Cytokine diversity in the Th1-dominated human anti-influenza response caused by variable cytokine expression by Th1 cells, and a minor population of uncommitted IL-2+IFNγ- Thpp cells. PLoS One (2014) 0.77

Human memory CD8 T cell effector potential is epigenetically preserved during in vivo homeostasis. J Exp Med (2017) 0.77

Smad4 represses the generation of memory-precursor effector T cells but is required for the differentiation of central memory T cells. Cell Death Dis (2015) 0.76

Naïve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment. Sci Rep (2016) 0.76

Nuclear PKC-θ facilitates rapid transcriptional responses in human memory CD4+ T cells through p65 and H2B phosphorylation. J Cell Sci (2016) 0.75

PKC-Theta is a Novel SC35 Splicing Factor Regulator in Response to T Cell Activation. Front Immunol (2015) 0.75

Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD8(+) T-cell differentiation. Immunology (2016) 0.75

Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09

Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04

Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity (2007) 12.98

mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07

Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 8.09

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell (2006) 7.49

Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature (2006) 5.90

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 5.54

Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol (2008) 4.88

A vital role for interleukin-21 in the control of a chronic viral infection. Science (2009) 4.55

Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity (2010) 4.52

Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity (2009) 4.42

The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity (2010) 4.21

T cells and viral persistence: lessons from diverse infections. Nat Immunol (2005) 4.12

Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity (2010) 4.06

Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation. J Immunol (2006) 3.73

A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity (2009) 3.66

Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity (2009) 3.66

Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity (2010) 3.49

β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell (2012) 3.33

JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 3.07

Role of TAZ as mediator of Wnt signaling. Cell (2012) 3.05

The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat Immunol (2011) 3.03

Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer (2012) 2.79

Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood (2007) 2.78

An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity (2011) 2.77

Generation of CD8 T cell memory is regulated by IL-12. J Immunol (2007) 2.69

E and ID proteins branch out. Nat Rev Immunol (2009) 2.68

Cutting edge: The transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J Immunol (2010) 2.63

YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol (2012) 2.59

WNT/beta-catenin pathway up-regulates Stat3 and converges on LIF to prevent differentiation of mouse embryonic stem cells. Dev Biol (2005) 2.54

Transcriptional regulator Id2 mediates CD8+ T cell immunity. Nat Immunol (2006) 2.43

Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile. Nat Immunol (2012) 2.26

Role for Bcl-6 in the generation and maintenance of memory CD8+ T cells. Nat Immunol (2002) 2.20

Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production. J Immunol (2007) 2.18

Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity (2011) 2.17

The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy. Immunity (2012) 2.15

A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity (2011) 2.15

The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets. Nat Immunol (2011) 2.10

Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory. Proc Natl Acad Sci U S A (2010) 2.05

CD4+ T cell regulation of CD25 expression controls development of short-lived effector CD8+ T cells in primary and secondary responses. Proc Natl Acad Sci U S A (2009) 2.01

Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. Nat Immunol (2011) 1.98

Secondary replicative function of CD8+ T cells that had developed an effector phenotype. Science (2009) 1.96

Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J Immunol (2007) 1.92

Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci U S A (2010) 1.85

Bcl6 acts as an amplifier for the generation and proliferative capacity of central memory CD8+ T cells. J Immunol (2004) 1.81

Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation. Immunity (2012) 1.69

Generating diversity: transcriptional regulation of effector and memory CD8 T-cell differentiation. Immunol Rev (2010) 1.65

A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity (2011) 1.58

Constitutive activation of Wnt signaling favors generation of memory CD8 T cells. J Immunol (2009) 1.54

Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51

Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J Immunol (2012) 1.48

IL-21 deficiency influences CD8 T cell quality and recall responses following an acute viral infection. J Immunol (2010) 1.28

Chemokine-guided CD4+ T cell help enhances generation of IL-6RalphahighIL-7Ralpha high prememory CD8+ T cells. J Immunol (2007) 1.21

Secondary T cell-T cell synaptic interactions drive the differentiation of protective CD8+ T cells. Nat Immunol (2013) 1.14

Beta-catenin does not regulate memory T cell phenotype. Nat Med (2010) 1.13

Effector and memory CD8+ T cell differentiation: toward a molecular understanding of fate determination. Curr Opin Immunol (2010) 1.11

Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. J Immunol (2011) 1.00

Cutting edge: β-catenin is dispensable for T cell effector differentiation, memory formation, and recall responses. J Immunol (2011) 1.00

Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell. Proc Natl Acad Sci U S A (2012) 0.98

Id2-mediated inhibition of E2A represses memory CD8+ T cell differentiation. J Immunol (2013) 0.96

Cutting edge: generation of memory precursors and functional memory CD8+ T cells depends on T cell factor-1 and lymphoid enhancer-binding factor-1. J Immunol (2012) 0.96

Loss of E protein transcription factors E2A and HEB delays memory-precursor formation during the CD8+ T-cell immune response. Eur J Immunol (2012) 0.92

Id2 influences differentiation of killer cell lectin-like receptor G1(hi) short-lived CD8+ effector T cells. J Immunol (2013) 0.88

Stimulation of Wnt/ß-catenin pathway in human CD8+ T lymphocytes from blood and lung tumors leads to a shared young/memory phenotype. PLoS One (2012) 0.81

Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56

CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 3.54

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood (2008) 3.52

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest (2007) 3.02

Identifying genes important for spermatogonial stem cell self-renewal and survival. Proc Natl Acad Sci U S A (2006) 2.84

Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A (2009) 2.56

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41

BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother (2010) 2.30

Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol (2004) 2.22

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A (2008) 2.07

Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06

High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther (2005) 2.04

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood (2010) 2.01

Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res (2011) 2.00

Secondary replicative function of CD8+ T cells that had developed an effector phenotype. Science (2009) 1.96

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82

The precursors of memory: models and controversies. Nat Rev Immunol (2009) 1.75

Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc (2012) 1.63

BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. Proc Natl Acad Sci U S A (2005) 1.61

Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60

Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol (2006) 1.51

Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51

MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51

Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother (2012) 1.47

Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med (2010) 1.45

Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med (2013) 1.40

Pillars Article: CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes. Science, 1992. 256: 105-107. J Immunol (2010) 1.40

Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation (2008) 1.32

Lineage relationship of effector and memory T cells. Curr Opin Immunol (2013) 1.30

Loss of T cell receptor-induced Bmi-1 in the KLRG1(+) senescent CD8(+) T lymphocyte. Proc Natl Acad Sci U S A (2007) 1.28

Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res (2007) 1.25

T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother (2008) 1.24

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer. J Transl Med (2012) 1.23

Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother (2012) 1.19

Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol (2005) 1.14

CD27 mediates interleukin-2-independent clonal expansion of the CD8+ T cell without effector differentiation. Proc Natl Acad Sci U S A (2006) 1.13

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol (2004) 1.12

A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther (2014) 1.05

Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J Immunother (2011) 1.04

Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection. J Immunol (2012) 1.04

CD8(+) T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway. Cancer Immunol Immunother (2006) 1.03

Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. J Exp Med (2013) 1.03

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood (2009) 0.99

Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell. Proc Natl Acad Sci U S A (2012) 0.98

In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother (2011) 0.96

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest (2015) 0.96

Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood (2008) 0.95

T-bet-mediated differentiation of the activated CD8+ T cell. Eur J Immunol (2010) 0.94

Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1. Cancer Immunol Res (2013) 0.91

Cutting edge: Virus-specific CD8+ T cell clones and the maintenance of replicative function during a persistent viral infection. J Immunol (2010) 0.87

Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep (2004) 0.80

The proto-oncogene BCL-6 is expressed in olfactory sensory neurons. Neurosci Res (2005) 0.79

The transcription factor BACH2 promotes tumor immunosuppression. J Clin Invest (2016) 0.78

Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? Int J Oncol (2003) 0.77

Control of HIV infection: escape from the shadow of Blimp-1. Eur J Immunol (2013) 0.76

Stubborn Tregs limit T-cell therapy. Blood (2012) 0.75

Unusual aspects of melanoma. Case 2. Regionally advanced nasal cavity melanoma. J Clin Oncol (2004) 0.75

siRNA high-throughput kinase library screen identifies protein kinase, DNA-activated catalytic polypeptide to play a role in MyD88-induced IFNA2 activation and IL-8 secretion. Biotechnol Appl Biochem (2012) 0.75